IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3000
-0.0361 (-10.74%)
At close: Dec 19, 2025, 4:00 PM EST
0.3100
+0.0100 (3.33%)
After-hours: Dec 19, 2025, 6:20 PM EST
IGC Pharma Revenue
IGC Pharma had revenue of $191.00K in the quarter ending September 30, 2025, a decrease of -53.64%. This brings the company's revenue in the last twelve months to $1.11M, down -6.51% year-over-year. In the fiscal year ending March 31, 2025, IGC Pharma had annual revenue of $1.27M, down -5.50%.
Revenue (ttm)
$1.11M
Revenue Growth
-6.51%
P/S Ratio
25.13
Revenue / Employee
$15,800
Employees
70
Market Cap
27.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.27M | -74.00K | -5.50% |
| Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
| Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
| Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
| Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
| Mar 31, 2020 | 4.07M | -1.04M | -20.41% |
| Mar 31, 2019 | 5.12M | 2.92M | 133.29% |
| Mar 31, 2018 | 2.19M | 1.61M | 277.86% |
| Mar 31, 2017 | 580.37K | -5.79M | -90.88% |
| Mar 31, 2016 | 6.37M | -1.31M | -17.10% |
| Mar 31, 2015 | 7.68M | 5.41M | 237.87% |
| Mar 31, 2014 | 2.27M | -5.76M | -71.69% |
| Mar 31, 2013 | 8.03M | 3.83M | 91.21% |
| Mar 31, 2012 | 4.20M | 125.63K | 3.08% |
| Mar 31, 2011 | 4.07M | -13.82M | -77.24% |
| Mar 31, 2010 | 17.90M | -17.44M | -49.35% |
| Mar 31, 2009 | 35.34M | 33.15M | 1,515.10% |
| Mar 31, 2008 | 2.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IGC News
- 9 hours ago - IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum - Accesswire
- 4 days ago - IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines - Accesswire
- 9 days ago - IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. - Accesswire
- 10 days ago - IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial - Accesswire
- 17 days ago - IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease - Accesswire
- 24 days ago - IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends - Accesswire
- 4 weeks ago - IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital - Accesswire
- 5 weeks ago - USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders - Accesswire